Overexpression of miR‑424‑5p reduces cisplatin resistance by downregulating SMURF1 in gastric cancer

Wang,Daohan; Cui,He; Yan,Yongjia; Fu,Weihua; Lu,Li

doi:10.3892/ol.2025.14889

Overexpression of miR‑424‑5p reduces cisplatin resistance by downregulating SMURF1 in gastric cancer

Authors:
- Daohan Wang
- He Cui
- Yongjia Yan
- Weihua Fu
- Li Lu
View Affiliations

Affiliations: Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China, Department of General Surgery, Tianjin Medical University General Hospital, Tianjin 300052, P.R. China
Published online on: January 15, 2025 https://doi.org/10.3892/ol.2025.14889
Article Number: 143
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Chemoresistance is a major obstacle in the treatment of gastric cancer (GC). Notably, aberrant expression of microRNAs (miRs) is closely related to tumor development and progression. In the present study, the role of miR‑424‑5p in the chemoresistance of GC was investigated. Reverse transcription‑quantitative PCR was used to detect the expression levels of miR‑424‑5p in tissues and different cell lines. Cell viability and apoptosis were detected via a Cell Counting Kit‑8 assay, western blotting and flow cytometry. The targeting relationship between miR‑424‑5p and SMAD‑specific E3 ubiquitin protein ligase 1 (SMURF1) was verified via dual‑luciferase reporter assays and the molecular mechanism was investigated by western blotting. The results revealed that miR‑424‑5p was expressed at low levels in GC tissues and cell lines, and that low miR‑424‑5p expression was associated with poor N stage and worse prognosis, especially in patients who received adjuvant chemotherapy. Further experiments revealed that the overexpression of miR‑424‑5p reduced cisplatin (CDDP) resistance and promoted GC cell apoptosis, whereas inhibiting miR‑424‑5p had the opposite effect. Mechanistically, it was found that miR‑424‑5p downregulated the expression of SMURF1 to regulate the expression of ING2 and p53, thereby modulating CDDP resistance in GC. In summary, the present study demonstrated that miR‑424‑5p may serve an important regulatory role in CDDP resistance in GC, and could be a potential diagnostic biomarker and therapeutic target for GC chemoresistance.

View Figures

View References

1	Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021. View Article : Google Scholar : PubMed/NCBI
2	Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI
3	Wei L, Sun J, Zhang N, Zheng Y, Wang X, Lv L, Liu J, Xu Y, Shen Y and Yang M: Noncoding RNAs in gastric cancer: Implications for drug resistance. Mol Cancer. 19:622020. View Article : Google Scholar : PubMed/NCBI
4	Rupaimoole R and Slack FJ: MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 16:203–222. 2017. View Article : Google Scholar : PubMed/NCBI
5	Zhang Q, Zhuang J, Deng Y, Yang L, Cao W, Chen W, Lin T, Lv X, Yu H, Xue Y and Guo H: miR34a/GOLPH3 axis abrogates urothelial bladder cancer chemoresistance via reduced cancer stemness. Theranostics. 7:4777–4790. 2017. View Article : Google Scholar : PubMed/NCBI
6	Peng Y, Hu S, Zhang K, Wang Y, Rouzi M, Zhou D and Yang R: Downregulation of microRNA-130a inhibits oral squamous cell carcinoma proliferation and metastasis via the hippo-YAP pathway. Cancer Manag Res. 13:4829–4840. 2021. View Article : Google Scholar : PubMed/NCBI
7	Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D and Bader AG: Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 70:5923–5930. 2010. View Article : Google Scholar : PubMed/NCBI
8	Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, Patrawala L, Yan H, Jeter C, Honorio S, et al: The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 17:211–215. 2011. View Article : Google Scholar : PubMed/NCBI
9	Trang P, Wiggins JF, Daige CL, Cho C, Omotola M, Brown D, Weidhaas JB, Bader AG and Slack FJ: Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 19:1116–1122. 2011. View Article : Google Scholar : PubMed/NCBI
10	Feng J, Lu SS, Xiao T, Huang W, Yi H, Zhu W, Fan S, Feng XP, Li JY, Yu ZZ, et al: ANXA1 binds and stabilizes EphA2 to promote nasopharyngeal carcinoma growth and metastasis. Cancer Res. 80:4386–4398. 2020. View Article : Google Scholar : PubMed/NCBI
11	Lu L, Wu M, Lu Y, Zhao Z, Liu T, Fu W and Li W: MicroRNA-424 regulates cisplatin resistance of gastric cancer by targeting SMURF1 based on GEO database and primary validation in human gastric cancer tissues. Onco Targets Ther. 12:7623–7636. 2019. View Article : Google Scholar : PubMed/NCBI
12	Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, Huang JJ, Ashby CR Jr and Chen ZS: Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 48:1006632020. View Article : Google Scholar : PubMed/NCBI
13	Xia Q, Li Y, Han D and Dong L: SMURF1, a promoter of tumor cell progression? Cancer Gene Ther. 28:551–565. 2021. View Article : Google Scholar : PubMed/NCBI
14	Nie J, Liu L, Wu M, Xing G, He S, Yin Y, Tian C, He F and Zhang L: HECT ubiquitin ligase Smurf1 targets the tumor suppressor ING2 for ubiquitination and degradation. FEBS Lett. 584:3005–3012. 2010. View Article : Google Scholar : PubMed/NCBI
15	Fu L, Cui CP, Zhang X and Zhang L: The functions and regulation of Smurfs in cancers. Semin Cancer Biol. 67:102–116. 2020. View Article : Google Scholar : PubMed/NCBI
16	Xia Q, Zhang H, Zhang P, Li Y, Xu M, Li X, Li X and Dong L: Oncogenic Smurf1 promotes PTEN wild-type glioblastoma growth by mediating PTEN ubiquitylation. Oncogene. 39:5902–5915. 2020. View Article : Google Scholar : PubMed/NCBI
17	Khammanivong A, Gopalakrishnan R and Dickerson EB: SMURF1 silencing diminishes a CD44-high cancer stem cell-like population in head and neck squamous cell carcinoma. Mol Cancer. 13:2602014. View Article : Google Scholar : PubMed/NCBI
18	Rich JT, Neely JG, Paniello RC, Voelker CC, Nussenbaum B and Wang EW: A practical guide to understanding Kaplan-Meier curves. Otolaryngol Head Neck Surg. 143:331–336. 2010. View Article : Google Scholar : PubMed/NCBI
19	Heid CA, Stevens J, Livak KJ and Williams PM: Real time quantitative PCR. Genome Res. 6:986–894. 1996. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Guo Z, Zhang X, Zhu H, Zhong N, Luo X, Zhang Y, Tu F, Zhong J, Wang X, He J and Huang L: TELO2 induced progression of colorectal cancer by binding with RICTOR through mTORC2. Oncol Rep. 45:523–534. 2021. View Article : Google Scholar : PubMed/NCBI
22	An Y, Wang B, Wang X, Dong G, Jia J and Yang Q: SIRT1 inhibits chemoresistance and cancer stemness of gastric cancer by initiating an AMPK/FOXO3 positive feedback loop. Cell Death Dis. 11:1152020. View Article : Google Scholar : PubMed/NCBI
23	Yang W, Ma J, Zhou W, Cao B, Zhou X, Yang Z, Zhang H, Zhao Q, Fan D and Hong L: Molecular mechanisms and theranostic potential of miRNAs in drug resistance of gastric cancer. Expert Opin Ther Targets. 21:1063–1075. 2017. View Article : Google Scholar : PubMed/NCBI
24	Czabotar PE, Lessene G, Strasser A and Adams JM: Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 15:49–63. 2014. View Article : Google Scholar : PubMed/NCBI
25	Hammond WA, Swaika A and Mody K: Pharmacologic resistance in colorectal cancer: A review. Ther Adv Med Oncol. 8:57–84. 2016. View Article : Google Scholar : PubMed/NCBI
26	Nies AT, Magdy T, Schwab M and Zanger UM: Role of ABC transporters in fluoropyrimidine-based chemotherapy response. Adv Cancer Res. 125:217–243. 2015. View Article : Google Scholar : PubMed/NCBI
27	Lee SD, Yu D, Lee DY, Shin HS, Jo JH and Lee YC: Upregulated microRNA-193a-3p is responsible for cisplatin resistance in CD44(+) gastric cancer cells. Cancer Sci. 110:662–673. 2019. View Article : Google Scholar : PubMed/NCBI
28	Zhu C, Huang Q and Zhu H: miR-383 inhibited the cell cycle progression of gastric cancer cells via targeting cyclin E2. DNA Cell Biol. 38:849–856. 2019. View Article : Google Scholar : PubMed/NCBI
29	Zhu M, Zhou X, Du Y, Huang Z, Zhu J, Xu J, Cheng G, Shu Y, Liu P, Zhu W and Wang T: miR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 14:1742–1750. 2016. View Article : Google Scholar : PubMed/NCBI
30	Du X, Liu B, Luan X, Cui Q and Li L: miR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med. 15:599–605. 2018.PubMed/NCBI
31	Pillai RS, Bhattacharyya SN and Filipowicz W: Repression of protein synthesis by miRNAs: How many mechanisms? Trends Cell Biol. 17:118–126. 2007. View Article : Google Scholar : PubMed/NCBI
32	Wang H: MicroRNAs and apoptosis in colorectal cancer. Int J Mol Sci. 21:53532020. View Article : Google Scholar : PubMed/NCBI
33	Min KH, Yang WM and Lee W: Saturated fatty acids-induced miR-424-5p aggravates insulin resistance via targeting insulin receptor in hepatocytes. Biochem Biophys Res Commun. 503:1587–1593. 2018. View Article : Google Scholar : PubMed/NCBI
34	Cheng D, Zhu C, Liang Y, Xing Y and Shi C: MiR-424 overexpression protects alveolar epithelial cells from LPS-induced apoptosis and inflammation by targeting FGF2 via the NF-kappaB pathway. Life Sci. 242:1172132020. View Article : Google Scholar : PubMed/NCBI
35	Wang Y, Lv Z, Fu J, Wang Z, Fan Z and Lei T: Endogenous microRNA-424 predicts clinical outcome and its inhibition acts as cancer suppressor in human non-small cell lung cancer. Biomed Pharmacother. 89:208–214. 2017. View Article : Google Scholar : PubMed/NCBI
36	Wu L, Yang F, Lin B, Chen X, Yin S, Zhang F, Xie H, Zhou L and Zheng S: MicroRNA-424 expression predicts tumor recurrence in patients with hepatocellular carcinoma following liver transplantation. Oncol Lett. 15:9126–9132. 2018.PubMed/NCBI
37	Wang ZX, Deng TX and Ma Z: Identification of a 4-miRNA signature as a potential prognostic biomarker for pancreatic adenocarcinoma. J Cell Biochem. 120:16416–16426. 2019. View Article : Google Scholar : PubMed/NCBI
38	Zhao C, Wang XB, Zhang YH, Zhou YM, Yin Q and Yao WC: MicroRNA-424 inhibits cell migration, invasion and epithelial-mesenchymal transition in human glioma by targeting KIF23 and functions as a novel prognostic predictor. Eur Rev Med Pharmacol Sci. 22:6369–6378. 2018.PubMed/NCBI
39	Xu J, Li Y, Wang F, Cheng B, Ye F, Xie X, Zhou C and Lu W: Suppressed miR-424 expression via upregulation of target gene Chk1 contributes to the progression of cervical cancer. Oncogene. 32:976–987. 2013. View Article : Google Scholar : PubMed/NCBI
40	Zhou Y, An Q, Guo RX, Qiao YH, Li LX, Zhang XY and Zhao XL: miR-424-5p functions as an anti-oncogene in cervical cancer cell growth by targeting KDM5B via the Notch signaling pathway. Life Sci. 171:9–15. 2017. View Article : Google Scholar : PubMed/NCBI
41	Bieg D, Sypniewski D, Nowak E and Bednarek I: MiR-424-3p suppresses galectin-3 expression and sensitizes ovarian cancer cells to cisplatin. Arch Gynecol Obstet. 299:1077–1087. 2019. View Article : Google Scholar : PubMed/NCBI
42	Geretto M, Pulliero A, Rosano C, Zhabayeva D, Bersimbaev R and Izzotti A: Resistance to cancer chemotherapeutic drugs is determined by pivotal microRNA regulators. Am J Cancer Res. 7:1350–1371. 2017.PubMed/NCBI
43	Xu S, Tao Z, Hai B, Liang H, Shi Y, Wang T, Song W, Chen Y, OuYang J, Chen J, et al: miR-424(322) reverses chemoresistance via T-cell immune response activation by blocking the PD-L1 immune checkpoint. Nat Commun. 7:114062016. View Article : Google Scholar : PubMed/NCBI
44	Song MK, Lee JH, Ryoo IG, Lee SH, Ku SK and Kwak MK: Bardoxolone ameliorates TGF-beta1-associated renal fibrosis through Nrf2/Smad7 elevation. Free Radic Biol Med. 138:33–42. 2019. View Article : Google Scholar : PubMed/NCBI
45	Tao Y, Sun C, Zhang T and Song Y: SMURF1 promotes the proliferation, migration and invasion of gastric cancer cells. Oncol Rep. 38:1806–1814. 2017. View Article : Google Scholar : PubMed/NCBI
46	Guo J, Xu G, Mao C and Wei R: Low expression of smurf1 enhances the chemosensitivity of human colorectal cancer to gemcitabine and cisplatin in patient-derived xenograft models. Transl Oncol. 13:1008042020. View Article : Google Scholar : PubMed/NCBI
47	Gozani O, Karuman P, Jones DR, Ivanov D, Cha J, Lugovskoy AA, Baird CL, Zhu H, Field SJ, Lessnick SL, et al: The PHD finger of the chromatin-associated protein ING2 functions as a nuclear phosphoinositide receptor. Cell. 114:99–111. 2003. View Article : Google Scholar : PubMed/NCBI